Intravitreal corticosteroid approved

Article

Trivaris (triamcinolone acetonide injectable suspension; Allergan), a synthetic glucocorticoid corticosteroid, has been approved by the FDA for the treatment of inflammatory ophthalmic conditions.

Trivaris (triamcinolone acetonide injectable suspension; Allergan), a synthetic glucocorticoid corticosteroid, has been approved by the FDA for the treatment of inflammatory ophthalmic conditions.

Trivaris 80 mg/mL has been indicated for sympathetic ophthalmia, temporal arteritis, uveitis and other conditions unresponsive to treatment with topical corticosteroids.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Martin David Harp
June 26th 2025
Article

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A digital rendering of the earth with a digital overlay to demonstrate technology. Concept image for global impact of myopia. Image credit: ©VFX – stock.adobe.com

Myopia’s global impact, by the numbers

Gregory Ostrow, MD;Laura Kirkeby, CO
June 25th 2025
Article

The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An illustration of an eye with computer chip in the iris. Concept image for artificial intelligence (AI), AI-READI project, fluorescence lifetime imaging ophthalmoscopy (FLIO) and retinal imaging. Image credit: ©okalinichenko – stock.adobe.com

The significance of FLIO in diabetic eye disease

Aaron Y. Lee, MD, MSCI;Sheryl Stevenson
June 23rd 2025
Article

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

A map or globe, with Europe emphasised under a magnifying glass. Concept image for European launch of Johnson and Johnson presbyopia-correcting Tecnis Odyssey IOL. Image credit: ©Pakawadee – stock.adobe.com

Johnson & Johnson launches presbyopia-correcting Tecnis Odyssey IOL in Europe

Martin David Harp
June 17th 2025
Article

The Tecnis Odyssey, launched in the US in October 2024, is now available in Europe, the Middle East and Canada

© 2025 MJH Life Sciences

All rights reserved.